XTL Biopharmaceuticals Ltd. (XTLB) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.70 (+5.60% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XTLB ranks #353 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XTLB carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRMA (Dermata Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and NRSN (NeuroSense Therapeutics Ltd.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M). Among the 5-stock peer group, XTLB leads on earnings multiple (N/A) while DRMA leads on capital efficiency (-35.0% ROIC).
For XTL Biopharmaceuticals Ltd. (XTLB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #353 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0% FCF Margin ($110.8K FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While XTLB currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.19) and Max Pain ($1.79) forces dealer call-delta covering toward $5.92.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
XTL Biopharmaceuticals Ltd. (XTLB) surged +5.60% to $1.70, trading at 2% of its 52-week range ($1.6 – $5.64). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
https://www.siam.in/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XTLB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XTLB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, XTL Biopharmaceuticals Ltd. (XTLB) ranks #353 by composite RQD confidence (46/100, grade D) and #957 by equity capitalization ($4.0M). Within this direct 5-issuer industry benchmark cohort, XTLB leads on earnings valuation at N/A trailing P/E, while DRMA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. XTLB currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XTLB
ACTIVE
XTL Biopharmaceuticals Ltd. | D | 46/100 | — | — | — | +5.60% | $4.0M | Benchmark Subject |
| DRMA Dermata Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -2.73% | $3.8M | /drma-vs-xtlb → |
| NRSN NeuroSense Therapeutics Ltd. | D- | 35/100 | — | — | -35.0% | -28.14% | $3.8M | /nrsn-vs-xtlb → |
| NCNA NuCana plc | D | 46/100 | — | — | — | -2.96% | $4.2M | /ncna-vs-xtlb → |
| MDCX Medicus Pharma Ltd. | E | 34/100 | — | — | -35.0% | +2.66% | $3.6M | /mdcx-vs-xtlb → |
XTL Biopharmaceuticals Ltd. (XTLB) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.70 (+5.60% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XTLB ranks #353 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XTLB carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRMA (Dermata Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and NRSN (NeuroSense Therapeutics Ltd.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M). Among the 5-stock peer group, XTLB leads on earnings multiple (N/A) while DRMA leads on capital efficiency (-35.0% ROIC).
For XTL Biopharmaceuticals Ltd. (XTLB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #353 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
XTLB last traded at $1.70 (+5.60% on volume of 12,984 shares), positioning the stock -22.37% below its 50-day simple moving average ($2.19) and -36.57% below its 200-day simple moving average ($2.68). Across its 52-week range of $1.60 to $5.64, XTLB sits at the 2.5% percentile with a 14-day RSI of 36.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.4% ($1.49 to $1.91).
XTLB scores 47 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Across its five pillars: Fundamental Cash Engine is 12 of 20 (ROIC 0%; FCF yield 0%), indicating no reported return on invested capital or free cash flow yield in the source data. Whale 13F Flow is 3 of 20, the lowest pillar, reflecting weak institutional accumulation and options positioning. Insider Conviction is 9 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit is 10 of 20 with a beta of 1.0. Forensic Balance Sheet is 13 of 20, supported by an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5. For a prospective investor, the rating points to a weak cash-generation profile and minimal institutional support, partly offset by a moderate balance-sheet reading. The source data contains no earnings, valuation multiples, or analyst targets against which upside could be measured, so the tradeoff between price and fundamentals cannot be quantified here.
. (XTLB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. —
Gross, operating, and net margins are each reported at 0%, and ROIC is 0%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5.
There are no upstream or downstream links and no proprietary signals recorded. Sector correlations and 2nd-order bottlenecks cannot be identified from the source data. —
Real-time company headlines, analyst actions, and sector developments for XTL Biopharmaceuticals Ltd. (XTLB) • Click "Debate This Headline" to argue it in the Roar Pit below
https://www.siam.in/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering XTL Biopharmaceuticals Ltd. (XTLB) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating XTL Biopharmaceuticals Ltd. (XTLB). Per the RQD rating, a moderate Forensic Balance Sheet score of 13/20 (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) suggests the company is not in distress on leverage metrics.. With an RQD score of 46/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.74.
@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
I respect the product at XTL Biopharmaceuticals Ltd., but the stock at $1.61 is a different story. Per the RQD rating, Whale 13F Flow scores only 3/20 and FCF yield and ROIC are both 0%, indicating weak institutional support and no reported cash generation.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).